Frankfurt - Delayed Quote EUR

Corcept Therapeutics Incorporated (HTD.F)

68.78

+1.18

+(1.75%)

At close: 9:48:34 PM GMT+2

New Strong Sell Stocks for May 29th

CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.

Zacks yesterday

CORT

MITT
1 Growth Stock with All-Star Potential and 2 to Avoid

Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.

StockStory 4 days ago

SOUNW

CORT

OPCH
Discover 3 Growth Stocks With Insider Ownership Up To 28%

Over the last 7 days, the United States market has experienced a 1.4% drop, but it remains up by 11% over the past year with earnings expected to grow by 14% annually in the coming years. In this context of fluctuating yet promising market conditions, growth stocks with significant insider ownership can be appealing as they often indicate confidence from those closest to the company's operations and potential for future success.

Simply Wall St. 7 days ago

CORT

CRWV

ALAB
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.

StockStory 8 days ago

CORT

CELG-RT

PFE
CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed

Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 2.2% above analysts’ estimates. Its non-GAAP profit of $0.17 per share was 19.3% above analysts’ consensus estimates.

StockStory 11 days ago

CORT
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.

StockStory 16 days ago

JAZZ

ANIP

VTRS
Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Corcept Therapeutics Incorporated's ( NASDAQ:CORT ) recent earnings report didn't offer any surprises, with the shares...

Simply Wall St. 18 days ago

CORT
Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other best performing healthcare stocks to buy now. Trump’s Healthcare Executive Order Brings a Win On April 15, CNBC reported that President Trump’s […]

Insider Monkey 19 days ago

CORT
1 Small-Cap Stock Worth Your Attention and 2 to Question

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

StockStory 22 days ago

WMS

CORT
Corcept Therapeutics price target lowered to $135 from $150 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, the analyst tells investors in a research note. More concerning is if demand for relacorilant, which is modeled to be a larger product, would be met if approved by December 30 PDUFA, the firm adds. Published first on TheFly – the ultimate

TipRanks 23 days ago

CORT
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS

Corcept Therapeutics (NasdaqCM:CORT) reported a decline in net income and earnings per share for Q1 2025, but maintained confidence by confirming its annual revenue guidance. This stable outlook occurred amid a market environment where major indices experienced some volatility, largely due to uncertainties surrounding tariffs and Federal Reserve decisions. Despite the market complexities, the company's 10.51% price increase over the last quarter aligns with the broader market movements...

Simply Wall St. 24 days ago

CORT
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.

Zacks 24 days ago

CORT
Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...

Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational hurdles and ongoing litigation.

GuruFocus.com 24 days ago

CORT
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 25 days ago

CORT
Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops

Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 2.2% above analysts’ estimates. Its GAAP profit of $0.17 per share was 20.8% above analysts’ consensus estimates.

StockStory 25 days ago

CORT
Corcept: Q1 Earnings Snapshot

REDWOOD CITY, Calif. AP) — Corcept Therapeutics Inc. CORT) on Monday reported first-quarter net income of $20.3 million.

Associated Press Finance 25 days ago

CORT
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REDWOOD CITY, Calif., May 05, 2025--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat serious endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2025.

Business Wire 25 days ago

CORT
Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against Billionaire Jim Simons’ RenTech’s other small-cap stock picks with huge upside potential. Jim Simons was (and still is even […]

Insider Monkey 26 days ago

CORT
Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings tomorrow after the bell. Here’s what to expect.

StockStory 26 days ago

CORT
Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?

We recently published a list of the 15 Best Growth Stocks to Buy for the Next 3 Years. In this article, we are going to take a look at where Corcept Therapeutics Inc. (NASDAQ:CORT) stands against other growth stocks to buy for the next 3 years. On April 29, Dan Ives of Wedbush Securities joined […]

Insider Monkey 29 days ago

CORT

Performance Overview

Return	HTD.F	S&P 500 (^GSPC)
YTD	+36.09%	+0.51%
1-Year	+139.07%	+12.92%
3-Year	+253.90%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Corcept Therapeutics Incorporated (HTD.F)

New Strong Sell Stocks for May 29th

1 Growth Stock with All-Star Potential and 2 to Avoid

Discover 3 Growth Stocks With Insider Ownership Up To 28%

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed

Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now

1 Small-Cap Stock Worth Your Attention and 2 to Question

Corcept Therapeutics price target lowered to $135 from $150 at Truist

Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS

CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall

Corcept Therapeutics Inc (CORT) Q1 2025 Earnings Call Highlights: Revenue Growth Amid ...

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

Corcept (NASDAQ:CORT) Misses Q1 Sales Targets, Stock Drops

Corcept: Q1 Earnings Snapshot

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

Is Corcept Therapeutics Inc. (NASDAQ:CORT) the Best Growth Stock to Buy for the Next 3 Years?

Performance Overview